Asset Details
Do you wish to reserve the book?
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
Do you wish to request the book?
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
2012
Overview
In this phase 2B trial involving 75 patients with acute ischemic stroke, tenecteplase was more effective than alteplase in achieving reperfusion and clinical improvement at 24 hours. Bleeding complications were similar in the two groups.
Thrombolytic treatment with alteplase, a recombinant tissue plasminogen activator, for acute ischemic stroke is of proven benefit.
1
However, alteplase is far from ideal, with incomplete and often delayed reperfusion in many patients.
2
Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has some pharmacokinetic advantages over alteplase.
3
A balance between efficacy and risk of bleeding in the treatment of stroke appears to be achieved at a lower dose of tenecteplase than the dose used for myocardial infarction.
4
A recent dose-ranging study of tenecteplase involving patients with acute ischemic stroke, which used standard clinical selection criteria, showed that a dose of 0.4 . . .
Publisher
Massachusetts Medical Society
Subject
/ Biological and medical sciences
/ Brain Ischemia - drug therapy
/ Dose-Response Relationship, Drug
/ Female
/ Fibrinolytic Agents - administration & dosage
/ Fibrinolytic Agents - adverse effects
/ Fibrinolytic Agents - therapeutic use
/ Humans
/ Ischemia
/ Male
/ NMR
/ Patients
/ Stroke
/ Tissue Plasminogen Activator - administration & dosage
/ Tissue Plasminogen Activator - adverse effects
/ Tissue Plasminogen Activator - therapeutic use
/ Vascular diseases and vascular malformations of the nervous system
